CSL Behring Signs Strategic Agreement With Enable Injections
CSL Behring LLC recently announced its affiliate company, CSL Behring AG, of Bern, Switzerland, and Enable Injections, LLC, of Franklin, OH, have signed a long-term development agreement for a new and innovative drug delivery system intended to improve the comfort, convenience, and treatment compliance for patients with rare and serious diseases.
As part of the strategic global collaboration, Enable will develop, manufacture, and sell its innovative treatment administration device, which was specifically designed for subcutaneous dosing, to CSL Behring for use with one of its products on an exclusive worldwide basis. CSL Behring has the option to add subsequent additional products and extend the term of the agreement for additional periods. CSL Behring and Enable have also agreed to discuss other potential subcutaneous product partnerships. Under the terms of the agreement, Enable will receive an upfront payment, as well as specific milestone payments over the next several years. Additional royalty payments are also called for throughout the course of the agreement. Further terms of the agreement were not disclosed.
“At CSL Behring, we are committed to serving patients with rare and serious diseases by providing treatments that save and extend lives,” said Bob Repella, Executive Vice President, Global Commercial Operations, CSL Behring. “One of the ways we do this is by focusing on medical advancements and new technologies that address patients’ needs and improve their quality of life. Through our collaboration with Enable Injections, we hope to bring patients a delivery option that makes administration of their therapy easier, helps improve treatment compliance, and offers them greater freedom and flexibility to treat their condition in a way that fits their individual needs.”
“People living with chronic diseases have to routinely manage their condition,” said Mike Hooven, CEO of Enable Injections. “Our innovative drug delivery system makes administering a life-long treatment easier and much more convenient. We are thrilled to partner with a scientific leader like CSL Behring to, upon regulatory approvals, bring this device to patients in the rare disease community who may benefit from our innovative drug delivery system.”
Enable Injections is a company that has developed a platform technology to deliver high viscosity/volume payloads up to 20 cc to the subcutaneous tissue. The system uses standard vial, syringe or cartridge container closure, and can automatically mix lyophilized solutions. CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide. For more information about CSL Behring, visit www.cslbehring.com, and for more information about Enable Injections, LLC, visit www.enableinjections.com.
Total Page Views: 1355
